27 completed, 11 recruiting, 8 not yet recruiting, 7 active not recruiting. 22 Phase 3, 14 Phase 2, 10 Phase 1, 3 Not applicable, 2 Phase 4.
Follow tezepelumab: new trials by email Literature Review of tezepelumab trials Research Report on tezepelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tezepelumab CRSwNP Real World Study (CREW Study) Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Not yet recruiting | AstraZeneca | 100 | 2026-10-01 | 2026-08-27 | |
| Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis Tezepelumab - Allergic Bronchopulmonary Aspergillosis, Severe Asthma | Not applicable | Not yet recruiting | Qianfoshan Hospital | 10 | 2026-09-01 | 2026-08-11 |
| Physical Activity Promotion and Clinical Remission in Severe Asthma Physical activity promotion, Tezepelumab - Severe Asthma | Not applicable | Recruiting | University of Leeds | 140 | 2026-07-31 | 2026-08-17 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) Tezepelumab, Placebo - Severe Asthma | Phase 4 | Recruiting | University of Alberta | 100 | 2026-05-11 | 2026-07-17 |
| A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-04-24 | 2026-10-16 |
| Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab Tezepelumab - Severe Asthma | Phase 3 | Recruiting | AstraZeneca | 400 | 2026-01-28 | 2026-09-03 |
| Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma tezepelumab (Arm1&Arm2) - Asthma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 636 | 2025-12-25 | 2025-12-24 |
| A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects QL2302, Tezspire - Healthy Participants | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 178 | 2025-12-22 | 2026-01-08 |
| Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps Tezepelumab - Asthma Bronchiale, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Not applicable | Not yet recruiting | Medical University of Vienna | 20 | 2025-10-01 | 2025-07-01 |
| Tezspire Cardiac Events PASS Tezepelumab - Cardiovascular Events, MACE | Recruiting | AstraZeneca | 16640 | 2025-09-15 | 2026-09-18 | |
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites | Phase 3 | Not yet recruiting | University Hospital, Montpellier | 38 | 2025-07-15 | 2025-06-10 |
| Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy Tezepelumab - Asthma | Active not recruiting | AstraZeneca | 315 | 2025-06-25 | 2026-07-20 | |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) Tezepelumab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Recruiting | AstraZeneca | 990 | 2025-03-25 | 2026-10-09 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) Tezepelumab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Recruiting | AstraZeneca | 990 | 2025-03-18 | 2026-09-03 |
| Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma Tezepelumab - Asthma, Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | Dr. Andrew Thamboo, MD | 10 | 2025-01-01 | 2024-12-18 |
| A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | AstraZeneca | 181 | 2024-12-03 | 2026-10-07 |
| Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) - Severe Asthma | Phase 3 | Active not recruiting | AstraZeneca | 310 | 2024-09-30 | 2026-10-13 |
| Tezepelumab Treatment in Korean Severe Asthma Patients Tezepelumab - Asthma | Not yet recruiting | Asan Medical Center | 100 | 2024-06-12 | 2024-06-03 |
Showing 20 of 57. Sign in to see all of them.
Asthma (33) · Pulmonary Disease, Chronic Obstructive (4) · Dermatitis, Atopic (3) · Respiratory Hypersensitivity (3) · Bronchial Diseases (2) · Eczema (2) · Hypersensitivity (2) · Immune System Diseases (2) · Lung Diseases (2) · Airway Remodeling (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bronchiolitis Obliterans Syndrome (1) · Chronic Urticaria (1) · Churg-Strauss Syndrome (1) · Coronary Artery Disease (1)
AstraZeneca (28) · Amgen (5) · MedImmune LLC (3) · McMaster University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Qilu Pharmaceutical Co., Ltd. (2) · University Hospital, Montpellier (2) · Asan Medical Center (1) · Asger Sverrild (1) · Celeste Porsbjerg (1) · Dr. Andrew Thamboo, MD (1) · Dr. Anne Ellis (1) · Hopital Foch (1) · Imperial College London (1) · Medical University of Vienna (1)
United States (23) · Canada (19) · Germany (15) · United Kingdom (14) · France (13) · Poland (11) · Japan (10) · South Korea (10) · Denmark (9) · Spain (9) · China (8) · Argentina (7) · Hungary (7) · Italy (7) · Australia (6)
Andrew Menzies-Gow, MD (2) · Dave Singh, MD (2) · Andrew Thamboo (1) · Anne K Ellis, MD (1) · Asger Sverrild, MD, PhD (1) · Celeste Porsbjerg, MD, PhD (1) · Chengshuo Wang, Professor (1) · Chris Brightling (1) · Dr. Rainard Fuhr (1) · Edwin H Kim, M.D., M.S. (1) · Enrico Heffler, MD, PhD (1) · Eric Simpson, MD (1) · FengMing Luo, Professor (1)
PMID 36702146, PMID 34358701, PMID 37015033, PMID 37772607, PMID 39326921, PMID 40285963, PMID 41072729, PMID 10109801, PMID 15823451, PMID 16226443, PMID 16478839, PMID 21893215, PMID 24846652, PMID 26337607, PMID 28500390, PMID 30185520, PMID 31613151, PMID 32729038, PMID 33050900, PMID 33050928, PMID 33050934, PMID 33087119, PMID 33169672, PMID 33368307, PMID 33380362, PMID 33907423, PMID 33979488, PMID 34049943, PMID 34256031, PMID 34403803, PMID 34779751, PMID 34913186, PMID 35364018, PMID 36223848, PMID 36253275, PMID 37263380, PMID 37619779, PMID 37723356, PMID 37914234, PMID 38064153, PMID 38320181, PMID 38697286, PMID 38749694, PMID 38802635, PMID 39514041, PMID 39653044, PMID 40388086, PMID 40782846, PMID 41317738, PMID 42148905
2014 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1)